The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
about
Prospects for dengue vaccines for travelersDengue Fever: Causes, Complications, and Vaccine StrategiesImplication of vaccination against dengue for Zika outbreakPatterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strainHuman CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificityAntibody responses to Zika virus infections in flavivirus-endemic environmentsVaccination strategies against Zika virusHistorical Perspectives on Flavivirus ResearchIn a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationThe 5' and 3' Untranslated Regions of the Flaviviral Genome.Current Status of Dengue Therapeutics Research and Development.In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.T-cell Responses in Individuals Infected with Zika Virus and in Those Vaccinated Against Dengue Virus.Immune correlates of protection for dengue: State of the art and research agenda.Working towards dengue as a vaccine-preventable disease: challenges and opportunities.Zika Virus: Immunity and Vaccine Development.Current management of severe dengue infection.Ghost probiotics with a combined regimen: a novel therapeutic approach against the Zika virus, an emerging world threat.Development of Peptide Vaccines in Dengue.Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.NIH dengue vaccine leaps into phase 3 studies.Dengue infection.Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas.Zika Vaccines: Role for Controlled Human Infection.Small Molecules and Antibodies for Zika Therapy.Advancing dengue vaccine development.Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.Taking a bite out of nutrition and arbovirus infection.Zika Virus Vaccine: Progress and ChallengesControlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine DevelopmentDengue vaccine aces trailblazing trial
P2860
Q26314423-6DA60905-C72F-4518-BB43-7AE42B236A79Q26700082-2D576764-6A2A-42B0-8CCF-05C18798CB1CQ27928012-031CE01F-0F32-481C-8A15-D188320D6272Q28729784-BC15EE05-0AF4-4117-96F8-824DF54CAB55Q28733418-DC6CE791-FA34-4D80-9646-6B6E4C056BB6Q28827957-ED8055A6-1ACF-431F-93E1-10414CDDB312Q29571224-D5A8AD2D-BE89-4CE9-88FF-738DCCE86043Q29994534-6DDBA0E0-175F-4AC8-8792-7F41DCAEA87FQ30250977-6C78EBF8-8826-4F25-8268-D39725A86432Q32183359-4DBC6732-2D5A-49B7-8AEB-BD78A01D315FQ33552896-A5E43D08-919D-4D68-A4A4-D961B9EDD983Q33867337-5BC39FC2-363E-4B1D-857A-8D4BC401EE88Q34522384-A80DCB8B-A8C0-460B-9F5A-961816477EB6Q38156586-E678C8D5-9A7B-444C-9063-3238461BC17AQ38652971-750112DC-5A0A-4315-B340-D0E57A3260CCQ38657783-B95E2157-15FC-4554-A3F2-3E50822FE530Q38969772-8BA5F70C-8D2C-4D1C-A57F-2D6525D4D527Q38992396-C9D82F3E-9E48-4694-9E3C-8506AE70EA7AQ40037758-A467894C-7DCD-4A12-9962-162E13673C70Q40038715-CA5603D6-B65C-43B4-B5B5-6B9EC7821984Q40040450-AD2D9CA2-B27D-498E-BA93-25982233FD62Q40053434-72D79645-8EAE-49E5-9E16-2E0926DE9EF0Q40066511-7F00EAC7-9553-4E19-BD39-6B1CD25251A4Q40107122-259CDB93-1C25-46B7-B8D4-7E57F4DC4093Q42996339-D35E2D89-1194-4693-B745-DAB0BF49B767Q43047038-FE06E107-4A1D-4F08-B0B8-8CDBF2F3792FQ47266530-8508FA7D-6445-4EF9-A5CB-C6220C9D713AQ47558373-E90EE756-3A9E-4353-94A4-3F959957E8A6Q49952058-93729660-6E90-4163-A6A1-A0ACCF531D22Q52662743-6B7922D0-1CC8-4407-94E6-B2F3A2480385Q55129301-04CE7932-FC70-422A-B3E4-A42EFEF2F365Q56347669-557478A3-3D3F-4ECE-911F-67D51A5EC305Q58699135-4A821576-475A-4D0A-B7D0-38374453E813Q74438495-6CAE4DAC-3B95-4191-A012-BE89AD0794EB
P2860
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The live attenuated dengue vac ...... ue in a human challenge model.
@en
type
label
The live attenuated dengue vac ...... ue in a human challenge model.
@en
prefLabel
The live attenuated dengue vac ...... ue in a human challenge model.
@en
P2093
P2860
P1476
The live attenuated dengue vac ...... ue in a human challenge model.
@en
P2093
Anna Janiak
Beth D Kirkpatrick
Beulah P Sabundayo
Catherine J Larsson
Catherine J Luke
Cecilia M Tibery
Kawsar R Talaat
Kristen K Pierce
Marya P Carmolli
Noreen A Hynes
P2860
P304
P356
10.1126/SCITRANSLMED.AAF1517
P407
P577
2016-03-16T00:00:00Z